164 related articles for article (PubMed ID: 35685498)
1. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
Surapat B; Kobpetchyok W; Kiertiburanakul S; Arnuntasupakul V
Int J Clin Pract; 2022; 2022():3098527. PubMed ID: 35685498
[TBL] [Abstract][Full Text] [Related]
2. Clinical Course and Outcomes among COVID-19 Patients at the Hospitel in Bangkok: A Retrospective Study.
Bruminhent J; Kaewsanga Y; Jiraaumpornpat W; Arnuntasupakul V; Suwatanapongched T; Kiertiburanakul S
Trop Med Infect Dis; 2022 Sep; 7(9):. PubMed ID: 36136649
[TBL] [Abstract][Full Text] [Related]
3. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
Ömeroğlu ŞK; Temel F; Altun D; Öztop B
Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
[TBL] [Abstract][Full Text] [Related]
4. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
5. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
[TBL] [Abstract][Full Text] [Related]
6. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
[TBL] [Abstract][Full Text] [Related]
7. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
8. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
[TBL] [Abstract][Full Text] [Related]
10. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Manabe T; Kambayashi D; Akatsu H; Kudo K
BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.
Ergür FÖ; Yıldız M; Şener MU; Kavurgacı S; Ozturk A
Sao Paulo Med J; 2022; 140(3):372-377. PubMed ID: 35507992
[TBL] [Abstract][Full Text] [Related]
12. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
[TBL] [Abstract][Full Text] [Related]
13. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Outcomes of Pediatric COVID-19 Pneumonia Treated with Favipiravir in a Tertiary Care Center.
Sitthikarnkha P; Phunyaissaraporn R; Niamsanit S; Techasatian L; Saengnipanthkul S; Uppala R
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932238
[TBL] [Abstract][Full Text] [Related]
15. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H
Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
[TBL] [Abstract][Full Text] [Related]
17. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
[TBL] [Abstract][Full Text] [Related]
18. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
[TBL] [Abstract][Full Text] [Related]
19. Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Sayiner A; Erdem HA; Korkmaz Ekren P; Tasbakan S; Basoglu OK; Tasbakan MI; Yamazhan T; Gokengin D; Ozhan MH
J Infect Dev Ctries; 2022 Mar; 16(3):422-426. PubMed ID: 35404846
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
